HK1255006A1 - 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 - Google Patents

制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 Download PDF

Info

Publication number
HK1255006A1
HK1255006A1 HK18114122.2A HK18114122A HK1255006A1 HK 1255006 A1 HK1255006 A1 HK 1255006A1 HK 18114122 A HK18114122 A HK 18114122A HK 1255006 A1 HK1255006 A1 HK 1255006A1
Authority
HK
Hong Kong
Prior art keywords
excipient
concentration
protein
ser
additive solution
Prior art date
Application number
HK18114122.2A
Other languages
English (en)
Chinese (zh)
Inventor
Judy Kay GLYNN
Brian Xin CHEN
Daniel Patrick Lacasse
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HK1255006A1 publication Critical patent/HK1255006A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18114122.2A 2015-09-22 2016-09-08 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 HK1255006A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222067P 2015-09-22 2015-09-22
US62/222067 2015-09-22
PCT/IB2016/055355 WO2017051273A1 (en) 2015-09-22 2016-09-08 Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method

Publications (1)

Publication Number Publication Date
HK1255006A1 true HK1255006A1 (zh) 2019-08-02

Family

ID=57045234

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114122.2A HK1255006A1 (zh) 2015-09-22 2016-09-08 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂

Country Status (11)

Country Link
US (1) US20230134160A1 (enExample)
EP (1) EP3352790A1 (enExample)
JP (1) JP6925111B2 (enExample)
KR (2) KR20200035496A (enExample)
CN (1) CN108025072A (enExample)
AU (1) AU2016329034B2 (enExample)
CA (1) CA2999118C (enExample)
HK (1) HK1255006A1 (enExample)
IL (1) IL258311B (enExample)
MX (1) MX2018003298A (enExample)
WO (1) WO2017051273A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. 難治性全身型重症筋無力症の処置のための方法
KR20200070355A (ko) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
CN112088013B (zh) * 2018-03-26 2024-12-06 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
WO2020006266A1 (en) * 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
EP3837273B1 (en) * 2018-08-14 2025-09-24 Bristol-Myers Squibb Company Improved protein recovery
CN111110841A (zh) * 2018-10-31 2020-05-08 上海君实生物医药科技股份有限公司 含有抗pcsk9抗体的稳定制剂
EP3782666B1 (en) 2019-01-24 2021-08-11 Magenta Medical Ltd. Manufacturing an impeller
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
WO2021171310A1 (en) * 2020-02-24 2021-09-02 Indian Institute Of Technology Delhi A system for real-time monitoring of protein and excipients
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
KR20230127292A (ko) * 2020-12-30 2023-08-31 아이-맵 바이오파마 컴파니 리미티드 항-cd73 항체의 제제
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
JP2025530825A (ja) 2022-09-14 2025-09-17 マジェンタ・メディカル・リミテッド 心室補助デバイスの湾曲
WO2024165043A1 (en) * 2023-02-08 2024-08-15 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by applying single-pass tangential flow filtration (sptff)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
DK1865986T3 (en) * 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
US8298535B2 (en) * 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EA022220B1 (ru) * 2010-02-24 2015-11-30 Сюменекс А/С Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы
WO2012168491A1 (en) * 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
BR112014028129A2 (pt) * 2012-05-14 2017-06-27 Novo Nordisk As soluções de proteína estabilizadas
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody

Also Published As

Publication number Publication date
WO2017051273A1 (en) 2017-03-30
EP3352790A1 (en) 2018-08-01
US20230134160A1 (en) 2023-05-04
KR20200035496A (ko) 2020-04-03
IL258311A (en) 2018-05-31
JP2017095440A (ja) 2017-06-01
AU2016329034B2 (en) 2019-05-23
CA2999118A1 (en) 2017-03-30
JP6925111B2 (ja) 2021-08-25
IL258311B (en) 2021-04-29
KR20180037056A (ko) 2018-04-10
RU2018110145A3 (enExample) 2020-02-10
CN108025072A (zh) 2018-05-11
AU2016329034A1 (en) 2018-03-15
MX2018003298A (es) 2018-06-20
RU2018110145A (ru) 2019-10-23
CA2999118C (en) 2022-06-14

Similar Documents

Publication Publication Date Title
HK1255006A1 (zh) 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂
JP7114567B2 (ja) 生体分子を含む高濃縮液体製剤の調製のためのプロセス
CN118994410A (zh) 通过将药物物质和药物产品过程整体化的生物制剂制造的连续制造过程
CN102245206A (zh) 获得无赋形剂抗体溶液的方法
US20160251441A1 (en) Antibody purification
KR20220063222A (ko) 고농축 단백질 제형에서 점도 감소제로서의 캄포술폰산 및 양이온성 부형제와 이의 조합
RU2779389C2 (ru) Способ получения терапевтического белкового препарата и препарат на основе антител, полученный по такому способу
JP2022508595A (ja) クロマトグラフィーを含まない抗体精製方法
US20240374720A1 (en) Antibody formulations and uses thereof